Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
September 30, 2022
NL
EN
Negma Group has converted 160 convertible bonds in Oxurion resulting in a EUR 400,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
Leuven, BELGIUM, Boston, MA, US – September 30, 2022 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of (i) 1,052,631 new ordinary shares on September 5, 2022, for a total amount of EUR 200,000, as the result of the conversion of 80 convertible bonds pursuant to the Capital Commitment entered into with Negma Group, and (ii) 1,052,631 new ordinary shares on September 13, 2022, for a total amount of EUR 200,000, as the result of the conversion of 80 convertible bonds pursuant to the Capital Commitment entered into with Negma Group.
Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 55,159,533 outstanding ordinary shares carrying voting rights (compared to 53,054,271 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
Share capital (EUR)
70,906,161.32
Total number of securities with voting rights (all ordinary shares)
55,159,533
Total number of ordinary shares (= denominator)
55,159,533
Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
719,500 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 719,500 securities carrying voting rights (all ordinary shares);
60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
1,007,250 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 1,007,250 securities carrying voting rights (all ordinary shares);
550,000 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 550,000 securities carrying voting rights (all ordinary shares);
739,499 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 739,499 securities carrying voting rights (all ordinary shares);
40 convertible bonds issued on August 5, 2022, entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the issuance and subscription agreement entered into between the Company and Negma Group on August 26, 2021;
1,080 convertible bonds issued on September 5, 2022, entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the issuance and subscription agreement entered into between the Company and Negma Group on August 26, 2021, and the addendum thereto dated September 2, 2022; and
100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Caym